Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000729593 | SCV000857267 | uncertain significance | not provided | 2017-10-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002533108 | SCV003284016 | uncertain significance | Peroxisome biogenesis disorder | 2022-04-10 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 308 of the PEX16 protein (p.Asp308His). This variant is present in population databases (rs749785179, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with PEX16-related conditions. ClinVar contains an entry for this variant (Variation ID: 594331). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002535124 | SCV003704008 | uncertain significance | Inborn genetic diseases | 2022-11-07 | criteria provided, single submitter | clinical testing | The c.922G>C (p.D308H) alteration is located in exon 10 (coding exon 10) of the PEX16 gene. This alteration results from a G to C substitution at nucleotide position 922, causing the aspartic acid (D) at amino acid position 308 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |